Back

UK Adds Patient-Reported Outcomes Resources to Digital Mental Health Collection

lite News Desk 2 min read

At a glance

  • New PROs resources for digital mental health added in October 2026.
  • Collection led by MHRA in partnership with NICE.
  • Guidance includes PROMs, PREMs, and digital collection methods.

The UK government has expanded its Digital Mental Health Technology (DMHT) collection with new resources on patient-reported outcomes, aiming to support the development and evaluation of digital mental health products.

The DMHT collection, available on GOV.UK, is managed by the Medicines and Healthcare products Regulatory Agency (MHRA) in collaboration with the National Institute for Health and Care Excellence (NICE). The addition of patient-reported outcomes (PROs) resources was published on 8 October 2026.

The collection offers a range of materials, including guidance on qualification and classification, standards from the British Standards Institution (BSI), and information on adverse event reporting. Other resources such as webinars, newsletters, research reports, and online learning modules are also included.

The DMHT project has been structured in phases, with the first phase starting in May 2023. The second phase began in May 2026 and is scheduled to continue until autumn 2028.

What the numbers show

  • PROs resources added to the DMHT collection on 8 October 2026.
  • Phase 1 of the DMHT project began in May 2023.
  • Phase 2 started in May 2026 and runs until autumn 2028.

The NICE evidence framework for digital health technologies, specifically tier C, recommends that comparative studies of digital mental health products should include patient-reported outcomes. This approach is intended to demonstrate the effectiveness of these products in practice.

Guidance within the collection explains the use of patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs) to evaluate the quality of care and patient experience. Electronic PROMs (ePROMs) are highlighted as a method for collecting data through digital devices such as smartphones, tablets, or kiosks.

By providing these resources, the DMHT collection aims to support developers, regulators, and healthcare professionals in assessing and improving digital mental health technologies using structured outcome and experience data.

* This article is based on publicly available information at the time of writing.

More from Health & Biotech

  1. The MHRA launched a Real-World Evidence guidance hub on October 9, 2026, to support regulatory decisions using real-world data, according to reports.

  2. The FDA approved Tukysa in combination with trastuzumab and pertuzumab for advanced HER2-positive breast cancer, according to Pfizer.

  3. A traveler from the Democratic Republic of Congo tested positive for Bundibugyo Ebola on October 3, 2026, according to health officials.

  4. The FDA approved Jaypirca for adults with untreated CLL or SLL without 17p deletion, marking it as the first non-covalent BTK inhibitor.

  5. A filing describes Roche’s NDA acceptance for fenebrutinib on September 30, 2026, according to the regulator. Priority review status was granted.